First-line Immunotherapy for Stomach Cancer
The FDA has approved pembrolizumab for the first-line treatment of certain HER2-negative gastric and gastroesophageal junction cancers. The U.S....
Progress Against Cancer
The FDA has approved pembrolizumab for the first-line treatment of certain HER2-negative gastric and gastroesophageal junction cancers. The U.S....
The FDA has approved repotrectinib for certain patients with non-small cell lung cancer harboring a ROS1 mutation or rearrangement. ...
The FDA has approved another inhibitor of the VEGF receptor family for patients with metastatic, heavily pretreated colorectal cancer. ...
The FDA has approved the immune checkpoint inhibitor pembrolizumab for certain advanced cancers of the biliary tract. The U.S....
The FDA has approved the immune checkpoint inhibitor toripalimab for some patients with nasopharyngeal carcinoma. The U.S. Food and...
The FDA has approved the IDH1 inhibitor ivosidenib for a group of blood cancers harboring an IDH1 mutation. The...
The FDA has approved the inhibitor entrectinib for some patients 1 month of age or older with solid tumors...
The FDA has approved pembrolizumab for the treatment of certain surgically removable tumors before and after resection. The U.S....
The FDA approved nivolumab for some patients with melanoma whose tumor was completely removed through surgery and has not...
The FDA approved encorafenib with binimetinib as a treatment for certain patients with non-small cell lung cancer. The U.S....